MAY 21, 2016 12:11 PM PDT

First Immunotherapy Drug Approved for Bladder Cancer

WRITTEN BY: Xuan Pham

For the first time in 30 years, the U.S. Food and Drug Administration approved a new drug for the treatment of the most common form of bladder cancer known as called urothelial carcinoma. The drug, Tecentriq (atezolizumab) is an immunotherapy agent that works by boosting the ability of body’s immune system to kill the cancer cells.

Image credit: Pixabay.com

“Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Products that block PD-1/PD-L1 interactions are part of an evolving story about the relationship between the body’s immune system and its interaction with cancer cells.”
 
Known as the programmed death ligand 1, PD-L1 binds to its receptors (PD-1), which are expressed by immune cells. The PD-L1/PD-1 pathway regulates the suppression of the immune system, and in under normal conditions, binding of the ligand to the PD-1 receptors protects healthy cells from tissue damage. However, cancer cells have learned to subvert this immune checkpoint by overexpressing the ligands, thus escaping the body’s natural defense attacks.

As a PD-L1 inhibitor, Tecentriq promotes more effective immune system attacks against the cancer. There are several anti-PD-1 drugs on the market. Most notably, nivolumab was recently approved for the treatment of non-small cell lung cancer (NSCLC). In the scope of bladder cancer, Tecentriq is the first of its class to be FDA approved.
 
The approval was based on clinical trial evidence showing that a significant number of patients with locally advanced or metastatic urothelial carcinoma responded well to Tecentriq. More specifically, of the 310 patients in the study, 15 percent experienced at least partial tumor shrinkage. These effects lasted from 2 to nearly 14 months, indicating good duration.
 
The study also found that patients with positive PD-L1 expression in the tumors responded better than those who didn’t express PD-L1. "While patients who received Tecentriq experienced a tumor response across the study, the greater effect in those who were classified as "positive" for PD-L1 expression suggests that the level of PD-L1 expression in tumor-infiltrating immune cells may help identify patients who are more likely to respond to treatment with Tecentriq."
 
Based on this, the FDA has also approved a corollary diagnostic test to detect PD-L1 expression in patients with bladder cancer. They hope this test will identify patients who will benefit most from Tecentriq.
 
As with most drugs, side-effects are unavoidable. For Tecentriq, these include fatigue, decreased appetite, nausea, urinary tract infection, fever, and constipation. The drug also increases risks for immune-related side effects involving major organs. 

Additional source: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 24, 2018
Cancer
JUL 24, 2018
Veterans with Cancer Get Streamlined Access to NCI Clinical Trials
Veterans with cancer, and the VA that cares for them, struggle to navigate the complex world of clinical trials but a collaborative agreement between VA and NCI could fix that....
AUG 07, 2018
Cancer
AUG 07, 2018
Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients
Targeted therapy for Bcl-2 may be helpful in more than the two lymphoma diagnoses that were recently approved by the FDA....
AUG 13, 2018
Videos
AUG 13, 2018
What does sunscreen look like with a UV camera?
  Have you ever wondered if there’s really a difference between SPF 30 and SPF 50? You’re not the only one. YouTuber Physics Girl set out...
AUG 14, 2018
Cancer
AUG 14, 2018
New Drug for Refractory Cutaneous T-cell Lymphoma
Mogamulizumab was approved by the FDA this month after a very successful Phase III clinical trial demonstrating its effectiveness in treating patients with challenging CTCL....
DEC 04, 2018
Immunology
DEC 04, 2018
Why is Skin Cancer so Elusive?
A pathway involved in skin cancer reveals a potential immunotherapy target...
DEC 06, 2018
Microbiology
DEC 06, 2018
A Bacterial Protein can Encourage Cancer Development
It's been suggested that a fifth of all cancers are caused by microbial infections, and new work indicates that the estimate is probably low....
Loading Comments...